The Indiana Biosciences Research Institute has named Alan Palkowitz president and chief executive officer. He will spend 80 percent of his time at IBRI, while maintaining his role at the Indiana University School of Medicine as senior research professor of medicine, where he directs the IUSM-Purdue TaRget Enablement to Accelerate Therapy Development for Alzheimer’s Disease (TREAT-AD) Center and is a key contributor to the IU Precision Health Initiative.
Dr. Palkowitz joined the faculty at IU School of Medicine in late 2018, as a senior research professor of medicine in the division of clinical pharmacology. Prior to that, he served as vice president of discovery chemistry research and technologies at Eli Lilly and Co. where he worked for 28 years.
Additionally, Dr. Palkowitz has served on several prominent advisory committees including most recently the NIH NCATS Advisory Council and the National Academy of Sciences Board on Chemical Sciences and Technologies. He has published numerous research articles and is an inventor on almost 60 US patents. Dr. Palkowitz obtained his PhD in synthetic organic chemistry from the Massachusetts Institute of Technology and his bachelor’s degree in chemistry from the University of California at Berkeley.